Free Trial

Beam Therapeutics (BEAM) Earnings Date, Estimates & Call Transcripts

Beam Therapeutics logo
$24.05 -2.26 (-8.59%)
(As of 11/15/2024 08:54 PM ET)

Beam Therapeutics Latest Earnings Summary

Upcoming Q4
Earnings Date
Feb. 25Estimated
Actual EPS
(Nov. 5)
-$1.17 Missed By -$0.01
Consensus EPS
(Nov. 5)
-$1.16

Beam Therapeutics posted Q3 2024 earnings on November 5, 2024, reporting an EPS of -$1.17, which missed the consensus estimate of -$1.16 by $0.01. Quarterly revenue fell 16.9% year-over-year to $14.30 million, below the consensus estimate of $14.52 million. With a trailing EPS of -$1.76, Beam Therapeutics' earnings are expected to grow next year, from ($4.66) to ($4.62) per share.

BEAM Upcoming Earnings

Beam Therapeutics' next earnings date is estimated for Tuesday, February 25, 2025, based off prior year's reporting schedules.


Skip Charts & View Estimated and Actual Earnings Data

BEAM Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

BEAM Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Beam Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20243-$1.31-$1.18-$1.26
Q2 20243-$1.24-$0.91-$1.08
Q3 20244-$1.23-$0.94-$1.09
Q4 20244-$1.31-$0.95-$1.14
FY 202414-$5.09-$3.98-$4.57
Q1 20253-$1.16-$0.90-$1.05
Q2 20253-$1.19-$0.90-$1.04
Q3 20253-$1.09-$0.90-$0.98
Q4 20253-$1.07-$0.86-$0.96
FY 202512($4.51)($3.56)($4.04)

Beam Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks
2/25/2025
(Estimated)
------- 
11/5/2024Q3 2024-$1.16-$1.17 -$0.01-$1.17$14.52M$14.30M    
8/6/2024Q2 2024-$1.13-$1.11+$0.02-$1.11$14.18M$11.80M  
5/7/2024Q1 2024-$1.42-$1.21+$0.21-$1.21$17.09M$7.40M  
2/27/2024Q4 2023-$0.69$1.73+$2.42$1.73$34.16M$316.20M  
11/8/2023Q3 2023-$1.33-$1.22+$0.11-$1.22$17.09M$17.20M  
8/8/2023Q2 2023-$1.42-$1.08+$0.34-$1.08$17.32M$20.12M  
THIS is even better than AI (Ad)

The all-new Apollo Smart Algo is revolutionizing trading as we know it... Not only has this first-of-its-kind “smart algo” been averaging 2.8 wins per day since inception… On stocks that are on the verge of breaking out… But it tells you exactly when to buy in before the big move could happen!

Click Here to Experience the Future of Trading. 
5/10/2023Q1 2023-$1.36-$1.33+$0.03-$1.33$14.41M$24.21M  
2/28/2023Q4 2022-$1.34-$0.54+$0.80-$0.54$12.73M$20.04M  

Beam Therapeutics Earnings - Frequently Asked Questions

Beam Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 25th, 2025 based off last year's report dates. Learn more on BEAM's earnings history.

In the previous quarter, Beam Therapeutics (NASDAQ:BEAM) missed the analysts' consensus estimate of ($1.16) by $0.01 with a reported earnings per share (EPS) of ($1.17). Learn more on analysts' earnings estimate vs. BEAM's actual earnings.

The conference call for Beam Therapeutics's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Beam Therapeutics's latest earnings report can be read online.
Read Transcript

Beam Therapeutics (NASDAQ:BEAM) has a recorded annual revenue of $377.71 million.

Beam Therapeutics (NASDAQ:BEAM) has a recorded net income of -$132.53 million. BEAM has generated -$1.76 earnings per share over the last four quarters.

Beam Therapeutics's earnings are expected to grow from ($4.66) per share to ($4.62) per share in the next year.

`

More Earnings Resources from MarketBeat



This page (NASDAQ:BEAM) was last updated on 11/18/2024 by MarketBeat.com Staff
From Our Partners